Research & Development

Innovative Glioblastoma Trial Targets Early Immunotherapy Use
Research & Development Innovative Glioblastoma Trial Targets Early Immunotherapy Use

Glioblastoma is an aggressive form of brain cancer with a median survival rate of just nine months post-diagnosis. This grim statistic raises important questions about the effectiveness of current treatments and the desperate need for new approaches. Consider the journey of many patients, whose

LEO's Anzupgo Cream: FDA-Approved Treatment for Chronic Hand Eczema
Research & Development LEO's Anzupgo Cream: FDA-Approved Treatment for Chronic Hand Eczema

Achieving the first FDA approval for moderate-to-severe chronic hand eczema (CHE), LEO Pharma's Anzupgo cream marks a pivotal development in dermatological treatments. Chronic hand eczema presents formidable challenges, affecting a significant portion of the adult population with its persistent

J&J Advances Immunology with Pathway-Centric Drug Strategy
Research & Development J&J Advances Immunology with Pathway-Centric Drug Strategy

Johnson & Johnson (J&J) is making significant strides in immunology drug development by embracing a pathway-centric approach to redefining autoimmune disease treatment under the leadership of Dr. Katie Abouzahr. This strategy diverges from traditional methods by prioritizing a multi-indication

Can Targeting Host Pathways Beat Cryptosporidium?
Research & Development Can Targeting Host Pathways Beat Cryptosporidium?

Cryptosporidium is an intestinal parasite causing severe diarrhea and particularly affects children and those with weakened immune systems, posing significant public health challenges. Efforts to find fully effective treatments have historically faced setbacks due to the organism's adaptability and

Gene Therapy Offers New Hope for Rett Syndrome Treatment
Research & Development Gene Therapy Offers New Hope for Rett Syndrome Treatment

Rett syndrome, a rare genetic disorder primarily affecting young girls, represents a profound medical challenge due to its debilitating symptoms and lack of a definitive cure. Originating from mutations in the MECP2 gene situated on the X chromosome, this condition leads to a deficiency in a

Can Roche's Itovebi Transform Breast Cancer Treatment?
Research & Development Can Roche's Itovebi Transform Breast Cancer Treatment?

The approval of Roche’s Itovebi marks a pivotal moment in breast cancer care, with the potential to significantly alter treatment strategies for ER-positive, HER2-negative breast cancer patients with PIK3CA mutations. The regulatory green light indicates a promising shift in oncology, specifically

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later